Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2025-02-05 00:00:00 ET · period of report 2025-02-03 · accession 0001628280-25-004085 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-05 | 2025-02-03 | RXRX | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +542.1K | 1.28M | +74% | $0 |
| D | 2025-02-05 | 2025-02-03 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $7.25 | -5,569 | 1.27M | -0.4% | -$40.4K |
| D | 2025-02-05 | 2025-02-03 | RXRX | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +1.05M | 1.05M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-02-03 | A | A | 525,283 | $0.00 | 1,261,916 | D | — | — | |
| 2 | Common | Class A Common Stock | 2025-02-03 | F | D | 5,569 | $7.25 | 1,273,156 | D | — | — | |
| 3 | Common | Class A Common Stock | 2025-02-03 | A | A | 16,809 | $0.00 | 1,278,725 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2025-02-03 | A | A | 1,050,567 | $0.00 | 1,050,567 | D | $7.25 · — to 2035-02-03 | 1,050,567 Class A Common Stock | (F4) The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |